Atmo Biosciences has moved to strengthen its United States commercial push, appointing seasoned medtech executive Martin Reid as Senior Vice President, Sales, as the company looks to build on early momentum following regulatory clearance and initial market entry.
The Melbourne and San Diego-based company, which is commercialising an ingestible gas-sensing capsule for gastrointestinal diagnostics, is accelerating its expansion in the US after securing FDA 510(k) clearance and launching in the Northeast in August 2025.
Since that entry, Atmo reports revenue growth of 700 per cent, with half of its sales coming from reorders, a signal that it is now seeking to scale up nationally as it raises capital to support further growth.
Reid, who will be based in California, steps into the role with more than two decades of experience in US medical device commercialisation, including building sales organisations, launching new technologies and expanding institutional access through integrated delivery networks and group purchasing organisations. His role will focus on driving adoption of hospital and specialty care, building distribution channels, and establishing a commercial infrastructure to support long-term growth in a competitive healthcare market.
Chief executive and president Malcolm Hebblewhite framed the appointment as coming at an inflection point for the company’s US strategy. “Martin joins Atmo at a pivotal point in our U.S. expansion,” he said. “He has repeatedly demonstrated the ability to translate innovative medical technologies into commercial traction at scale, and his experience building high-performing sales organisations will be instrumental as we grow our presence across the US.”
Reid most recently served as Vice President of Sales at EndoGastric Solutions, where he led national commercial operations, oversaw revenue growth from early-stage commercialisation to more than US$30 million annually, and built a 42-person sales team. The company was ultimately acquired by Merit Medical during his tenure.
Earlier roles include senior leadership positions at Olympus Corporation, where he managed an 80-person, multi-region sales team generating US$75 million in annual revenue, and at Johnson & Johnson’s Sedasys division, where he led the national launch of an anaesthesia platform, scaling revenue from zero to US$10 million within 18 months. He has also held commercial leadership roles at Boston Scientific and Given Imaging, consistently driving market share growth and product adoption across both emerging and established medtech organisations.
Reid said the opportunity at Atmo reflected both the underlying clinical need and the company’s differentiated technology platform. “Atmo is developing a genuinely differentiated diagnostic platform to address large unmet clinical needs,” he said. “I’m excited to work with the team to build a focused, disciplined US commercial engine that supports clinicians, delivers value to health systems, and positions the company for sustained growth.”